How fast up the ladder? Factors associated with immunosuppressive or anti-TNF therapies in IBD patients at early stages: results from a population-based cohort

International Journal of Colorectal Disease

Volumn 29, Issue 11, 2014, Pages 1329-1338

  Ott, Claudia ^a   Takses, Angela ^a   Obermeier, Florian ^a   Schnoy, Elisabeth ^a   Salzberger, Bernd ^a   Müller, Martina ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Accelerated step up; Anti TNF therapy; Azathioprine; Crohn s disease; Immunosuppressive therapy; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CORTICOSTEROID THERAPY; CROHN DISEASE; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK FACTOR; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE; DRUG ADMINISTRATION; ONSET AGE; PROSPECTIVE STUDY;

ADRENAL CORTEX HORMONES; AGE OF ONSET; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84920989800     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-014-2002-z     Document Type: Article

References (38)

1. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A (2011) Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140(6):1785–1794
2. Hanauer SB, Present DH (2003) The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 3(2):81–92
3. Lowenberg M, D’Haens G (2012) Mucosal healing in Crohn’s disease: relevance for clinical outcomes. Curr Drug Targets 13(10):1248–1251
4. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S et al.(2010) Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology, 138(2):463–468; quiz e410-461.
5. Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S (2008) Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 28(6):674–688
6. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353(23):2462–2476
7. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359(9317):1541–1549
8. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD et al (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132(1):52–65
9. Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Robinson AM, Huang B, Lomax KG, Pollack PF (2013) Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease. J Crohn’s Colitis 7(3):213–221
10. Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Scholmerich J, Panes J, Sandborn WJ (2010) Increased response and remission rates in short-duration Crohn’s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 105(7):1574–1582
11. D’Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A et al (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 371(9613):660–667
12. Solberg IC, Lygren I, Jahnsen J, Aadland E, Hoie O, Cvancarova M, Bernklev T, Henriksen M, Sauar J, Vatn MH et al (2009) Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 44(4):431–440
13. Solberg IC, Vatn MH, Hoie O, Stray N, Sauar J, Jahnsen J, Moum B, Lygren I (2007) Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 5(12):1430–1438
14. Cosnes J, Bourrier A, Nion-Larmurier I, Sokol H, Beaugerie L, Seksik P (2012) Factors affecting outcomes in Crohn’s disease over 15 years. Gut 61(8):1140–1145
15. Burger D, Travis S (2011) Conventional medical management of inflammatory bowel disease. Gastroenterology, 140(6):1827–1837 e1822.
16. Sands BE (2012) The risks and benefits of early immunosuppression and biological therapy. Dig Dis 30(Suppl 3):100–106
17. Ordas I, Feagan BG, Sandborn WJ (2011) Early use of immunosuppressives or TNF antagonists for the treatment of Crohn’s disease: time for a change. Gut 60(12):1754–1763
18. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J (2006) Predictors of Crohn’s disease. Gastroenterology 130(3):650–656
19. Lakatos PL, Czegledi Z, Szamosi T, Banai J, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp J et al (2009) Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn’s disease. World J Gastroenterol 15(28):3504–3510
20. Loly C, Belaiche J, Louis E (2008) Predictors of severe Crohn’s disease. Scand J Gastroenterol 43(8):948–954
21. Romberg-Camps MJ, Dagnelie PC, Kester AD, de Kruijs MA H-v, Cilissen M, Engels LG, Van Deursen C, Hameeteman WH, Wolters FL, Russel MG et al (2009) Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 104(2):371–383
22. Wolters FL, Russel MG, Sijbrandij J, Ambergen T, Odes S, Riis L, Langholz E, Politi P, Qasim A, Koutroubakis I et al (2006) Phenotype at diagnosis predicts recurrence rates in Crohn’s disease. Gut 55(8):1124–1130
23. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr (2010) Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology 139(4):1147–1155
24. Roth LS, Chande N, Ponich T, Roth ML, Gregor J (2010) Predictors of disease severity in ulcerative colitis patients from Southwestern Ontario. World J Gastroenterol 16(2):232–236
25. Hoie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T, Odes S, Mouzas IA, Beltrami M, Langholz E et al (2007) Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 102(8):1692–1701
26. Ott C, Obermeier F, Thieler S, Kemptner D, Bauer A, Scholmerich J, Rogler G, Timmer A (2008) The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study. Eur J Gastroenterol Hepatol 20(9):917–923
27. Gasche C, Scholmerich J, Brynskov J, D’Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ et al (2000) A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 6(1):8–15
28. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D’Haens G, D’Hoore A, Mantzaris G, Novacek G et al (2012) Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohn’s Colitis 6(10):991–1030
29. Dignass A, Preiss JC, Aust DE, Autschbach F, Ballauff A, Barretton G, Bokemeyer B, Fichtner-Feigl S, Hagel S, Herrlinger KR et al (2011) Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Z Gastroenterol 49(9):1276–1341
30. Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, Danese S, D’Hoore A, Gassull M, Gomollon F et al (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohn’s Colitis 4(1):28–62
31. Hoffmann JC, Preiss JC, Autschbach F, Buhr HJ, Hauser W, Herrlinger K, Hohne W, Koletzko S, Krieglstein CF, Kruis W et al (2008) Clinical practice guideline on diagnosis and treatment of Crohn’s disease. Z Gastroenterol 46(9):1094–1146
32. Lakatos PL, Golovics PA, David G, Pandur T, Erdelyi Z, Horvath A, Mester G, Balogh M, Szipocs I, Molnar C et al (2012) Has there been a change in the natural history of Crohn’s disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977–2009. Am J Gastroenterol 107(4):579–588
33. Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, Langholz E, Thomsen OO, Munkholm P (2007) Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 13(4):481–489
34. Mossop H, Davies P, Murphy MS (2008) Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 47(2):123–129
35. Chow DK, Sung JJ, Wu JC, Tsoi KK, Leong RW, Chan FK (2009) Upper gastrointestinal tract phenotype of Crohn’s disease is associated with early surgery and further hospitalization. Inflamm Bowel Dis 15(4):551–557
36. Lau A, Chande N, Ponich T, Gregor JC (2008) Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 28(5):606–613
37. Szamosi T, Banai J, Lakatos L, Czegledi Z, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp M et al (2010) Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn’s disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol 22(7):872–879
38. Rubin DT, Uluscu O, Sederman R (2012) Response to biologic therapy in Crohn’s disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis 18(12):2225–2231